Empagliflozin directly improves diastolic function in human heart failure

Cited by (225)

Items 101–200 of 225

1. Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats
   Roxana Pérez‐Villavicencio, Javier Flores‐Estrada, Martha Franco, Bruno Escalante, Oscar A Pérez-Méndez, Adriana Mercado, Rocío Bautista‐Pérez · 2022 · International Journal of Molecular Sciences
2. Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story
   Massimiliano Camilli, Péter Ferdinándy, Emanuela Salvatorelli, Pierantonio Menna, Giorgio Minotti · 2024 · Progress in Cardiovascular Diseases
3. Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro
   Yasmin Moustafa Ahmed, Basim Anwar Shehata Messiha, Mahmoud El‐Daly, Ali A. Abo‐Saif · 2019 · Pharmacological Reports
4. Heart failure with preserved ejection fraction: insights from recent clinical researches
   Mi‐Na Kim, Seong‐Mi Park · 2020 · The Korean Journal of Internal Medicine
5. Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies
   Haipeng Wang, Lin Ding, Liwen Tian, Yutian Tian, Lin Liao, Junyu Zhao · 2022 · Frontiers in Endocrinology
6. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
   Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli‐Ducci, Daniele Torella, Isabella Leo · 2024 · Cardiovascular Diabetology
7. Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
   Rosalinda Madonna, Filippo Biondi, Mattia Alberti, Sandra Ghelardoni, Letizia Mattii, Alberto D’Alleva · 2024 · Biomedicine & Pharmacotherapy
8. Leveraging metabolism for better outcomes in heart failure
   Yann Huey Ng, Yen Chin Koay, Francine Z. Marques, David M. Kaye, John O’Sullivan · 2024 · Cardiovascular Research
9. Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF
   Sarah Costantino, S A Mohammed, Samuele Ambrosini, Marialucia Telesca, Alessandro Mengozzi, Kaivalya Walavalkar, Era Gorica, Melissa Herwig, Loek van Heerebeek, Junyan Xia et al. · 2025 · Circulation Research
10. Heart Failure With Preserved Ejection Fraction: An Evolving Understanding
    Sunanda Tah, Melissa Valderrama, Maham Afzal, Javed Iqbal, Aisha Farooq, Muhammad Ali Lak, Karol Gostomczyk, Elhama Jami, Mahendra Kumar, Akshay Sundaram et al. · 2023 · Cureus
11. Potential roles of sodium‐glucose co‐transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure
    Tanawat Attachaipanich, Siriporn Chaisin Chattipakorn, Nipon Chattipakorn · 2022 · Journal of Cellular Physiology
12. Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes
    Fail T. Ageev, Artem G. Ovchinnikov · 2022 · Kardiologiia
13. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
    John W. Ostrominski, Muthiah Vaduganathan · 2023 · The American Journal of Medicine
14. Fisiopatologia e Tratamento da Insuficiência Cardíaca com Fração de Ejeção Preservada: Estado da Arte e Perspectivas para o Futuro
    Sara Lopes Fernandes, Rita Ribeiro Carvalho, Luís Graça Santos, Fernando Montenegro Sá, Catarina Ruivo, Sofia Lazaro Mendes, Hélia Martins, João Morais · 2019 · Arquivos Brasileiros de Cardiologia
15. Heart failure with preserved ejection fraction: insights from recent clinical researches
    Mi‐Na Kim, Seong‐Mi Park · 2020 · The Korean Journal of Internal Medicine
16. NLRP3 Inflammasome: A New Target for the Treatment of CVD and Depression Comorbidity
    Chen Chen, Siqi Zhang, Ming Sheng, Wei Shao · 2025 · Mediators of Inflammation
17. Heart failure with preserved ejection fraction: a stepchild no more!
    Eugene Braunwald M. D · 2021 · European Heart Journal
18. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
    Inês Aguiar‐Neves, Diogo Santos‐Ferreira, Ricardo Fontes‐Carvalho · 2023 · Reviews in Cardiovascular Medicine
19. Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View
    Silvia Prosperi, Andrea D’Amato, Paolo Severino, Vincenzo Myftari, Sara Monosilio, Ludovica Marchiori, Lucrezia Maria Zagordi, Domenico Filomena, Gianluca Di Pietro, Lucia Ilaria Birtolo et al. · 2023 · International Journal of Molecular Sciences
20. Effects of empagliflozin on right ventricular adaptation to pressure overload
    Julie Birkmose Axelsen, Anders Hammer Nielsen-Kudsk, Janne Schwab, Steffen Ringgaard, Jens Erik Nielsen‐Kudsk, Frances S. de Man, Asger Andersen, Stine Andersen · 2023 · Frontiers in Cardiovascular Medicine
21. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions
    Andrea Passantino, Caterina Rizzo, Domenico Scrutinio, Alberto Palazzuoli · 2021 · Heart Failure Reviews
22. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
    Lei Tian, Sinan Ai, Huijuan Zheng, Hanwen Yang, Mengqi Zhou, Jingyi Tang, Weijing Liu, Wenjing Zhao, Yaoxian Wang · 2022 · Frontiers in Pharmacology
23. Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction
    Elisa Dal Canto, Mariëlle Scheffer, Kirsten A. Kortekaas, Annet Driessen‐Waaijer, Walter J. Paulus, Loek van Heerebeek · 2023 · Biomedicines
24. Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice
    Xiehong Liu, Huiqi Zhao, Sisi Liu, Siao Wen, Wenjuan Fan, Qiong Xie, Bo Cui, Lin Zhou, Jianqiang Peng, Hongwei Pan et al. · 2025 · Frontiers in Cardiovascular Medicine
25. Sleeve Gastrectomy Ameliorates Diabetes-Induced Cardiac Hypertrophy Correlates With the MAPK Signaling Pathway
    Qian Xu, Huanxin Ding, Songhan Li, Shuohui Dong, Linchuan Li, Bowen Shi, Mingwei Zhong, Guangyong Zhang · 2021 · Frontiers in Physiology
26. Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF
    Guodong Pan, Bipradas Roy, Shailendra Giri, David E. Lanfear, Rajarajan A. Thandavarayan, Ashrith Guha, Pablo Alfredo Ortiz, Suresh S. Palaniyandi · 2022 · International Journal of Molecular Sciences
27. The Mechanisms Associated with Inflammation and Coronary Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction
    Xiaoli Yan, Ruxia Wang, Hui Xu, Zhongbin Tao, Jizu Ling · 2025 · Medical Principles and Practice
28. Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study
    Fahad M. Althobaiti, Safaa Alsanosi, Alaa Hisham Falemban, Abdullah Rzgallah Alzahrani, Salma A. Fataha, Sara O. Salih, Ali M. Alrumaih, Khalid N. Alotaibi, Hazim M. Althobaiti, Saeed Alghamdi et al. · 2022 · Journal of Clinical Medicine
29. New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold
    Edoardo Sciatti, Lucia Dallapellegrina, Marco Metra, Carlo Lombardi · 2019 · Journal of Cardiovascular Medicine
30. The role of diabetes in cardiomyopathies of different etiologies—Characteristics and 1-year follow-up results of the EVITA-HF registry
    Christine Meindl, Matthias Hochadel, Lutz Frankenstein, Oliver Bruder, Matthias Pauschinger, Rainer Hambrecht, Wolfgang von Scheidt, Otmar Pfister, Andreas Hartmann, Lars Siegfried Maier et al. · 2020 · PLoS ONE
31. SGLT2 inhibitors: how do they affect the cardiac cells
    Betül Rabia Erdoğan, Ebru Arioglu‐Inan · 2024 · Molecular and Cellular Biochemistry
32. The challenges of an aging tetralogy of Fallot population
    Jennifer P. Woo, Doff B. McElhinney, George K. Lui · 2021 · Expert Review of Cardiovascular Therapy
33. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview
    Loredana Nicoleta Ionică, Adina V. Furdui-Lința, Alina D. Bătrîn, Iasmina M. Hâncu, Bogdan M. Lolescu, Maria D. Dănilă, Lucian Petrescu, Ioana Monica Mozos, Adrian Sturza, Danina Mirela Muntean · 2024 · International Journal of Molecular Sciences
34. From support to recovery: the evolving role of LVAD in reversing heart failure
    Bingqi Sun, Zhigang Liu · 2025 · Journal of Cardiothoracic Surgery
35. The impact of using SGLT-2 inhibitor on left ventricular longitudinal strain and NT-proBNP levels during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction
    Halil İbrahim Biter, Sinem Deniz Cakal, Beytullah Çakal, Ziya Aapaydin, Ali Yaşar Kılınç, Huseyin Oguz, Sinan Yildiz, Hasan Ogur, Erdal Belen, Emel Simsek · 2024 · Kardiologia Polska
36. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
    Bo Liang, Yitao Liang, N. Gu · 2022 · BMC Cardiovascular Disorders
37. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
    Taichi Minami, Akiko Kameda, Yasuo Terauchi · 2021 · Expert Opinion on Pharmacotherapy
38. Diving into the Unknown: Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure without Diabetes
    Petar M Seferovic, Jelena P. Seferović, Marija M. Polovina · 2019 · European Journal of Heart Failure
39. The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction
    Sanne G.J. Mourmans, Anouk Achten, Raquel Hermans, Marijne J. E. Scheepers, Elisa D’Alessandro, Geertje Swennen, Janneke Woudstra, Yolande Appelman, Harry van Goor, Casper G. Schalkwijk et al. · 2025 · Cardiovascular Diabetology
40. Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction
    Michele Alfieri, Filippo Bruscoli, Luca Di Vito, Federico Di Giusto, Giancarla Scalone, Procolo Marchese, Domenico Delfino, Simona Silenzi, Milena Martoni, Federico Guerra et al. · 2024 · Journal of Cardiovascular Development and Disease
41. Atrial Fibrillation in End-Stage Heart Failure: Cellular Mechanisms Behind CASTLE-HTx
    Maria Knierim, Nico Hartmann, Wiebke Maurer, Steffen Pabel, Simon Sedej, Dirk von Lewinski, Jan Fritz Gummert, Christian Sohns, Katrin Streckfuß‐Bömeke, Samuel Tobias Sossalla · 2025 · European Journal of Heart Failure
42. Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment
    Nicola C. Edwards, Davor Pavlovic, Charles Joseph Ferro, John Townend · 2026 · Nature Reviews Cardiology
43. Exploring the therapeutic potential of tetrahydrobiopterin for heart failure with preserved ejection fraction: A path forward
    Weiyi Xia, Miao Zhang, Chang Liu, Sheng Wang, Aimin Xu, Zhengyuan Xia, Lei Pang, Yin Cai · 2024 · Life Sciences
44. Sodium-glucose co-transporter 2 inhibitors and heart failure—the present and the future
    Melanie Nana, Holly Morgan, L. N. Rao Bondugulapati · 2020 · Heart Failure Reviews
45. Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study
    Artem G. Ovchinnikov, A. A. Borisov, Kristina Zherebchikova, О.Ю. Рябцева, Анна Дмитриевна Гвоздева, Valery P. Masenko, Fail T. Ageev, Sergey Anatol'evich Boytsov · 2021 · Russian Journal of Cardiology
46. A mechanistic rationale for the investigation of sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article ‘Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial’
    Steffen Pabel, Nazha Hamdani, Samuel Tobias Sossalla · 2020 · European Journal of Heart Failure
47. Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trial
    Costa, Kevin D., Wong, Andy O. T., Mak, Suet Yee, Roberts, Erin G., Keung, Wendy, Correia, Claudia, Walentinsson, Anna, Christoffersson, Jonas, Cheung, Alice, Lieu, Deborah K. et al. · 2024 · bioRxiv
48. SGLT2 inhibitors: Do they have antiarrhythmic properties?
    Ricardo Caballero, Juan Luis Tamargo, Eva Delpón · 2026 · Pharmacology & Therapeutics
49. Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
    Mauro Gori, Emilia D’Elia, Edoardo Sciatti, Michele Senni · 2022 · Cardiac failure review
50. The emerging concept of glycocalyx damage as the trigger of heart failure onset and progression
    Ryszard Targoński, Magdalena Kowacz, Rafał Oraczewski, Michael Allen Thoene, Radosław Targoński · 2023 · Medical Hypotheses
51. The effect of empagliflozin on P wave peak time and other P wave parameters in patients with diabetes mellitus
    Burhan Aslan, Abdurrahman Akyüz, Ferhat Işık, Bedrettin Boyraz, Ümit İnci, Halil Yıldız, Murat Çap, Mehmet Zülküf Karahan, Eşref Araç, Metin Okşul et al. · 2022 · Pacing and Clinical Electrophysiology
52. The effect of empagliflozin on index of cardio‐electrophysiological balance in patients with diabetes mellitus
    Ümit İnci, Tuncay Güzel · 2022 · Pacing and Clinical Electrophysiology
53. The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
    Mauro Gitto, Alessandro Villaschi, Massimo Federici, Gianluigi Condorelli, Giulio Giuseppe Stefanini · 2023 · Current Pharmaceutical Design
54. Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
    Zhicheng Gao, Jiaqi Bao, Yilan Hu, Junjie Tu, Lifang Ye, Lihong Wang · 2023 · Current Drug Targets
55. Cardiovascular Outcomes of Perioperative Sodium‐Glucose Transporter 2 Inhibition in Cardiac Surgery Patients: An Open‐Label Randomized Pilot Study
    Lars I. P. Snel, Maartina J P Oosterom-Eijmael, Yugeesh R. Lankadeva, Mark Philip Plummer, Benedikt Preckel, Coert Jozef Zuurbier, Jeroen Hermanides, Daniël H. van Raalte, Abraham Hendrikus Hulst · 2025 · Acta Anaesthesiologica Scandinavica
56. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study
    Claus Jünger, Jürgen H. Prochaska, Tommaso Gori, Andreas Schulz, Harald Binder, Andreas Daiber, Thomas Koeck, Steffen Rapp, Karl Johannes Lackner, Thomas F. Münzel et al. · 2021 · Journal of Cardiovascular Medicine
57. Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
    He Ying Sun, Zhongqing Wang, Yuxi Wang, Haichuan Rong, Danyang Wang, Xiangnian Liu, Ke Jin, Zhicheng Sun, Qiuling Fan · 2023 · Frontiers in Pharmacology
58. Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
    Леонова Марина Васильевна · 2024 · Consilium Medicum
59. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies
    Rayla Rodrigues Soares, Larissa Freitas Viggiani, Juliano Moreira Reis Filho, Julliane Vasconcelos Joviano‐Santos · 2024 · Chemico-Biological Interactions
60. Improvements of cardiac function and metabolic parameters by sodium-glucose cotransporter 2 inhibitors with no significant effects on sympathetic or parasympathetic activity in chronic heart failure
    Jinya Takahashi, Yoshihiro Fukumoto · 2025 · Heart and Vessels
61. A Comprehensive Review on Sodium Glucose Co-Transporter-2 Inhibitors-Empagliflozin
    Sanjaana Arun, D Praveen, Ranadheer Chowdary Puvvada, Vijey Aanandhi Muthukumar · 2022 · Research Journal of Pharmacy and Technology
62. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
    Christian Alfons Schneider, Roman Pfister · 2022 · Herz
63. Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?
    Francesco Paneni, Sebastiano Sciarretta, Sarah Costantino · 2020 · Cardiovascular Research
64. Empagliflozin mitigates doxorubicin-induced hepatotoxicity by reducing inflammation, oxidative stress, and apoptosis in male NMRI mice
    Nafiseh Asgari, Zahra Kalhori · 2025 · Medical Oncology
65. How Does It Work? Unraveling the Mysteries by Which Empagliflozin Helps Diabetic and Non-diabetic Patients With Heart Failure
    Vernicia K Hernandez, Brad T Parks Melville, Khadijah Siwaju · 2023 · Cureus
66. The effect of SGLT2 inhibitors on cardio-electrophysiological balance index in diabetic patients with preserved ejection heart failure
    Gokhan Gökalp, Nail Burak Özbeyaz · 2023 · Archives of Current Medical Research
67. Factors associated with risk analysis for asymptomatic left ventricular diastolic dysfunction in nondialysis patients with chronic kidney disease
    Yajuan Gao, Shengnan Chen, Jiani Fu, Cui Wang, Yali Tang, Yongbai Luo, Xiaozhen Zhuo, Xueying Chen, Yan Shen · 2024 · Renal Failure
68. Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction: A Narrative Review
    Rafik Maged, Mohit Sinha, Hema Manvi Koneru, Hooria Sarwar, Venkata Varshitha Bandi, Pakeeza Tarar, Nouran Halawa · 2024 · Cureus
69. Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
    Dana Darwish, Pooja Kumar, Khushi Urs, Siddharth Dave · 2025 · Cells
70. Sodium–Glucose Co-Transporter 2 Inhibitors: ‘a Tale of Two Sisters’, Diabetes and Heart Failure
    Dimitrios T. Farmakis, Javed Butler, Gerasimos S Filippatos · 2020 · European Journal of Heart Failure
71. Effect of empagliflozin on the left ventricular diastolic function in patients with type 2 diabetes mellitus and concomitant heart failure with preserved ejection fraction
    Andrii S. Herashchenko, Sergiy V. Fedorov, M.V. Bielinskyi, Nestor M. Seredyuk, Bohdan Lyubomyrovych Henyk · 2023 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
72. Carvedilol Activates a Myofilament Signaling Circuitry to Restore Cardiac Contractility in Heart Failure
    Ying Wang, Meimi Zhao, Xianhui Liu, Bing Xu, Gopireddy Raghavender Reddy, Aleksandra Jovanović, Qingtong Wang, Chaoqun Zhu, Heli Xu, Elizabeth F. Bayne et al. · 2024 · JACC Basic to Translational Science
73. Phenotypic Features of Heart Failure in Patients with Preserved Left Ventricular Ejection Fraction
    Мустафина Ирина Аликовна, Margarita R. Plotnikova, Yu. N. Belenkov, Natalia V. Khabarova, Naufal Sh. Zagidullin · 2025 · Kardiologiia
74. Possibilities of cardio- and nephroprotective eff ects of drugs of the SGLT2 inhibitor group
    Курашин Владимир Константинович, N. Yu. Borovkova, V. A. Kurashina, T. E. Bakka · 2021 · Clinical Medicine (Russian Journal)
75. The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes
    Hayder Adnan Fawzi, Reeman Sabbar, Sinaa Abdul Amir Kadhim, Ali Flayih, Bassim I. Mohammad, Asma A Swadi · 2024 · Journal of Medicine and Life
76. The effect of sodium-glucose cotransporter type 2 inhibitors on left ventricular diastolic function: current status and prospects
    Ekaterina V. Borisova, Антон Владимирович Барсуков, Глебова Светлана Анатольевна, Anna A. Airapetian · 2024 · Kardiologiia
77. Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease
    Donna Shu‐Han Lin, Hao-Yun Lo, Chung‐Wei Yang, Chih‐Cheng Wu · 2025 · American Journal of Cardiovascular Drugs
78. Diabetes and Cardiometabolic Care, Pharmacotherapy, and Patient Outcomes in Two Regional Aboriginal Primary Care Health Centres: Lessons to be Learnt
    Annabelle G Hayes, Odette R. Pearson, Chinmay S. Marathe, David R. Jesudason · 2025 · Heart Lung and Circulation
79. The SGLT-2 Inhibitor Empagliflozin Improves Myocardial Strain, Reduces Cardiac Fibrosis and Pro-Inflammatory Cytokines in Non-Diabetic Mice Treated With Doxorubicin
    Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea, Antônio Barbieri, Maria Gaia Monti, Antonietta Caronna, Annamaria Bonelli, Gerardo Botti, Nicola Maurea · 2020
80. Chromatin Remodeling by the Histone Methyltransferase SETD2 Drives Lipotoxic Injury in Cardiometabolic Heart Failure with Preserved Ejection Fraction
    Samuele Ambrosini, Sarah Costantino, S A Mohammed, Era Gorica, Melissa Herwig, Loek van Heerebeek, Alessandro Mengozzi, Gergely Karsai, Thorsten Hornemann, Omer Dzemali et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
81. Figures of the Heart Failure Association (HFA): Prof. Dr. med. Thomas Thum, Chair of the ESC Working Group on Myocardial Function and Ex-Officio HFA Board Member (2018–2020)
    Andrew J.S. Coats · 2019 · European Journal of Heart Failure
82. A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
    D. P. Golubovskaia, В. Н. Каретникова, И. Р. Олейник, О. Л. Барбараш · 2022 · Rational Pharmacotherapy in Cardiology
83. Beyond Glycemic Control: Mechanistic Insights Into SGLT-2 Inhibitors in Heart Failure Management
    Shreya Garg, Sai Gautham Kanagala, FNU Anamika, Kinna Parikh, Harmanjit Kaur, Nikita Garg, Rohit Jain · 2023 · Cardiology in Review
84. Repurposing of Empagliflozin as Cardioprotective Drug: An in-silico Approach
    Jyoti Yadav, Farogh Ahsan, Prabhudatta Panda, Tarique Mahmood, Shahzadi Bano, Arshiya Shamim, Pooja Mishra · 2024 · Cardiovascular & Haematological Disorders - Drug Targets
85. Empagliflozin-mediated protection of heparan sulfate-rich endothelial glycocalyx during vascular inflammation
    Natalia Chorazy, Kamila Wojnar‐Lason, Anna M. Gdula, Benedikt Fels, Marta Stojak, Agnieszka Karaś, Manga Motrapu, Hans‐Joachim Anders, Kristina Kusche‐Vihrog, Marta Z. Pacia · 2026 · Biochemical Pharmacology
86. Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression
    Juliana Mira Hernández, Logan R.J. Bailey, Victoria Salemme, Christopher Y. Ko, Erin Y. Shen, Megan Ngim, Duong Hoang, Melissa Corea, Julie Bossuyt, Jennifer Davis et al. · 2026 · Basic Research in Cardiology
87. Mechanobiology of the diabetic cardiomyocyte: insulin signaling, titin elasticity, and multiscale mechanical dysfunction
    M Kacmaz, E Halupka, Innas Sultana, Simin Delalat, Ibrahim El‐Battrawy, Muchtiar Khan, Loek van Heerebeek, Nazha Hamdani · 2026 · Biophysical Reviews
88. Reducing Cardiac Steatosis: Interventions to Improve Diastolic Function: A Narrative Review
    Kiyan Heshmat‐Ghahdarijani, Roya Modaresi, Sobhan Pourmasjedi, Setayesh Sotoudehnia Korani, Ali Rezazadeh Roudkoli, Razieh Ziaei, Armita Farid, Mehrnaz Salehi, Afshin Heidari, Sina Neshat · 2023 · Current Problems in Cardiology
89. From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes
    Fernando Grover‐Páez, Arantza Maya Gómez, A. Suárez, Andrea Martínez Echauri · 2023 · IntechOpen eBooks
90. EMPAGLIFLOZIN MITIGATES CHEMOTHERAPY-INDUCED CARDIOTOXICITY AND ENDOTHELIAL DYSFUNCTION IN BREAST CANCER PATIENTS
    M.V. Bielinskyi, Sergiy V. Fedorov, S. B. Herashchenko, Andrii S. Herashchenko, I. V. Kozlova, Taras Havrysh · 2024 · World of Medicine and Biology
91. Empagliflozin in heart failure patients with preserved ejection fraction and diabetes mellitus type 2. (Results of a pilot prospective randomized trial)
    Artem G. Ovchinnikov, A.A. Borisov, Kristina Zherebchikova, О.Ю. Рябцева, Анна Дмитриевна Гвоздева, Valery P. Masenko, Fail T. Ageev · 2021 · Russian Cardiology Bulletin
92. The Effects of Low-dose Empagliflozin on Cardiac Function in a Rat Model of Streptozotocin-induced Diabetes
    Zeynep Eilf Yesilyurt, İrem Karaömerlioğlu, Betül Rabia Erdoğan, Gaye Ozturk, Martin Christian Michel, Ebru Arioglu‐Inan · 2021 · Research Square
93. Empagliflozin's Anti-Inflammatory Spectrum in Type 2 Diabetes Mellitus: Piecing Together the Puzzle
    Sophie Van Linthout, Frank Spillmann, Subodh Verma · 2025 · European Journal of Heart Failure
94. December 2018 at a Glance: New Imaging Methods, Translational Cardiology and Non-Medical Treatment
    Marco Metra · 2018 · European Journal of Heart Failure
95. Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature
    Elisa Fabbri, Maurizio Nizzoli · 2019 · Italian Journal of Medicine
96. Physiological monitoring of the complex multimorbid heart failure patient – diabetes and monitoring glucose control
    Petar M Seferovic, Pardeep S. Jhund · 2019 · European Heart Journal Supplements
97. Mechanisms Underlying Cardiovascular Benefits of Sodium Glucose Co-Transporter-2 Inhibitors: Myocardial Substrate or Sodium/Hydrogen Exchanger?
    Hana E. Baker · 2020 · IUScholarWorks (Indiana University)
98. Kardiovaskuläre Effekte von SGLT-2-Inhibitoren
    Julian Mustroph, Stefan Neef · 2020 · Diabetes aktuell
99. Medikamentöse Therapie bei Herzinsuffizienz mit erhaltener Pumpfunktion
    Tobias Daniel Trippel, Carsten Tschöpe · 2020 · DMW - Deutsche Medizinische Wochenschrift
100. A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'
     Samuel Tobias Sossalla, Steffen Pabel, Nazha Hamdani · 2020 · University of Regensburg Publication Server (University of Regensburg)